INSM Key Stats
- Slightly Negative but Still Frothy May 20
- Small-Caps Out Front May 20
- Trumping Market Skepticism May 20
- Requiem for the Bears May 17
- Digging for New Buys May 17
- Insmed rises as analyst forecasts gains for stock May 15
- Unusual 11 Mid-Day Movers 05/15: (MFLR) (CHCI) (NYNY) Higher; (SVNT) (XONE) (WTT... May 15
- Sailing on a Sea of Liquidity May 15
- Back to the Future? May 15
- 2 BioPharma Catalyst Trades And 1 Strong Acquisition Target Rumored To Be In Pla... May 15
INSM Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Insmed is up 305.2% over the last year vs S&P 500 Total Return up 31.59%, ACADIA Pharmaceuticals up 896.5%, and Array BioPharma up 58.10%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for INSM
Pro Report PDF for INSM
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download INSM Pro Report PDF
Pro Strategies Featuring INSM
Did Insmed make it into our Pro Portfolio Strategies?